Immunoproteomics: The key to discovery of new vaccine antigens against bacterial respiratory infections

Current Protein and Peptide Science

Volumn 13, Issue 8, 2012, Pages 807-815

  Dennehy, Ruth ^a   McClean, Siobhán ^a  

^a DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

Author keywords

Antigens; Immunoproteomics; Immunoreactive proteins; Respiratory disease; Vaccine; Virulence

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; OUTER MEMBRANE PROTEIN; PSEUDOMONAS VACCINE; VACCINE;

BACTERIAL INFECTION; BORDETELLA PERTUSSIS; BURKHOLDERIA PSEUDOMALLEI; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPROTEOMICS; NEISSERIA MENINGITIDIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEOMICS; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL INFECTIONS; BACTERIAL VACCINES; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEOMICS; RESPIRATORY TRACT INFECTIONS;

EID: 84874922941     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920312804871184     Document Type: Review

References (66)

1. Septimus, E.J.; Kuper, K.M. Clinical challenges in addressing resistance to antimicrobial drugs in the twenty-first century. Clin. Pharmacol. Ther., 2009, 86, 336-339.
2. DiGiandomenico, A.; Rao, J.; Harcher, K.; Zaidi, T.S.; Gardner, J.; Neely, A.N.; Pier, G.B.; Goldberg, J.B. Intranasal immunization with heterologously expressed polysaccharide protects against multiple pseudomonas aeruginosa infections. Proc. Natl. Acad. Sci. USA., 2007, 104, 4624-4629.
3. Kellner, J. Update on the success of the pneumococcal conjugate vaccine. Paediatr. Child Health, 2011, 16, 233-240.
4. Kidd, P. Th1/th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev., 2003, 8, 223-246.
5. Pizza, M.; Scarlato, V.; Masignani, V.; Giuliani, M.M.; Arico, B.; Comanducci, M.; Jennings, G.T.; Baldi, L.; Bartolini, E.; Capecchi, B.; Galeotti, C.L.; Luzzi, E.; Manetti, R.; Marchetti, E.; Mora, M.; Nuti, S.; Ratti, G.; Santini, L.; Savino, S.; Scarselli, M.; Storni, E.; Zuo, P.; Broeker, M.; Hundt, E.; Knapp, B.; Blair, E.; Mason, T.; Tettelin, H.; Hood, D.W.; Jeffries, A.C.; Saunders, N.J.; Granoff, D.M.; Venter, J.C.; Moxon, E.R.; Grandi, G.; Rappuoli, R. Identification of vaccine candidates against serogroup b meningococcus by whole-genome sequencing. Science, 2000, 287, 1816-1820.
6. O'Brien, K.L.; Wolfson, L.J.; Watt, J.P.; Henkle, E.; Deloria-Knoll, M.; McCall, N.; Lee, E.; Mulholland, K.; Levine, O.S.; Cherian, T. Burden of disease caused by streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet, 2009, 374, 893-902.
7. Lifshitz, S.; Dagan, R.; Shani-Sekler, M.; Grossman, N.; Fleminger, G.; Friger, M.; Nebenzahl, Y.M. Age-dependent preference in human antibody responses to streptococcus pneumoniae polypeptide antigens. Clin. Exp. Immunol., 2002, 127, 344-353.
8. McCool, T.L.; Cate, T.R.; Moy, G.; Weiser, J.N. The immune response to pneumococcal proteins during experimental human carriage. J. Exp. Med., 2002, 195, 359-365.
9. Ling, E.; Feldman, G.; Portnoi, M.; Dagan, R.; Overweg, K.; Mulholland, F.; Chalifa-Caspi, V.; Wells, J.; Mizrachi-Nebenzahl, Y. Glycolytic enzymes associated with the cell surface of streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse. Clin. Exp. Immunol., 2004, 138, 290-298.
10. Daniely, D.; Portnoi, M.; Shagan, M.; Porgador, A.; Givon-Lavi, N.; Ling, E.; Dagan, R.; Mizrachi Nebenzahl, Y. Pneumococcal 6- phosphogluconate-dehydrogenase, a putative adhesin, induces protective immune response in mice. Clin. Exp. Immunol., 2006, 144, 254-263.
11. Mizrachi Nebenzahl, Y.; Bernstein, A.; Portnoi, M.; Shagan, M.; Rom, S.; Porgador, A.; Dagan, R. Streptococcus pneumoniae surface-exposed glutamyl trna synthetase, a putative adhesin, is able to induce a partially protective immune response in mice. J. Infect. Dis., 2007, 196, 945-953.
12. Morsczeck, C.; Prokhorova, T.; Sigh, J.; Pfeiffer, M.; Bille-Nielsen, M.; Petersen, J.; Boysen, A.; Kofoed, T.; Frimodt-Moller, N.; Nyborg-Nielsen, P.; Schrotz-King, P. Streptococcus pneumoniae: Proteomics of surface proteins for vaccine development. Clin. Microbiol. Infect., 2008, 14, 74-81.
13. Choi, C.W.; Lee, Y.G.; Kwon, S.O.; Kim, H.Y.; Lee, J.C.; Chung, Y.H.; Yun, C.Y.; Kim, S.I. Analysis of streptococcus pneumoniae secreted antigens by immuno-proteomic approach. Diagn. Microbiol. Infect. Dis., 2012, 72, 318-327.
14. Harding, S.V.; Sarkar-Tyson, M.; Smither, S.J.; Atkins, T.P.; Oyston, P.C.; Brown, K.A.; Liu, Y.; Wait, R.; Titball, R.W. The identification of surface proteins of burkholderia pseudomallei. Vaccine, 2007, 25, 2664-2672.
15. Riedel, K.; Carranza, P.; Gehrig, P.; Potthast, F.; Eberl, L. Towards the proteome of burkholderia cenocepacia h111: Setting up a 2-de reference map. Proteomics, 2006, 6, 207-216.
16. Kim, H.S.; Schell, M.A.; Yu, Y.; Ulrich, R.L.; Sarria, S.H.; Nierman, W.C.; DeShazer, D. Bacterial genome adaptation to niches: Divergence of the potential virulence genes in three burkholderia species of different survival strategies. BMC Genomics, 2005, 6, 174.
17. Chen, D.J.; Osterrieder, N.; Metzger, S.M.; Buckles, E.; Doody, A.M.; DeLisa, M.P.; Putnam, D. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl. Acad. Sci. USA., 2010, 107, 3099-3104.
18. Oster, P.; O'Hallahan, J.; Aaberge, I.; Tilman, S.; Ypma, E.; Martin, D. Immunogenicity and safety of a strain-specific menb omv vaccine delivered to under 5-year olds in new zealand. Vaccine, 2007, 25, 3075-3079.
19. Nieves, W.; Asakrah, S.; Qazi, O.; Brown, K.A.; Kurtz, J.; Aucoin, D.P.; McLachlan, J.B.; Roy, C.J.; Morici, L.A. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary burkholderia pseudomallei infection. Vaccine, 2011, 29, 8381-8389.
20. Allwood, E.M.; Logue, C.A.; Hafner, G.J.; Ketheesan, N.; Norton, R.E.; Peak, I.R.; Beacham, I.R. Evaluation of recombinant antigens for diagnosis of melioidosis. FEMS Immunol. Med. Microbiol., 2008, 54, 144-153.
21. Hara, Y.; Mohamed, R.; Nathan, S. Immunogenic burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets. PLoS One, 2009, 4, e6496.
22. Su, Y.C.; Wan, K.L.; Mohamed, R.; Nathan, S. A genome level survey of burkholderia pseudomallei immunome expressed during human infection. Microbes. Infect., 2008, 10, 1335-1345.
23. Su, Y.C.; Wan, K.L.; Mohamed, R.; Nathan, S. Immunization with the recombinant burkholderia pseudomallei outer membrane protein omp85 induces protective immunity in mice. Vaccine, 2010, 28, 5005-5011.
24. Suwannasaen, D.; Mahawantung, J.; Chaowagul, W.; Limmathurotsakul, D.; Felgner, P.L.; Davies, H.; Bancroft, G.J.; Titball, R.W.; Lertmemongkolchai, G. Human immune responses to burkholderia pseudomallei characterized by protein microarray analysis. J. Infect. Dis., 2011, 203, 1002-1011.
25. Druar, C.; Yu, F.; Barnes, J.L.; Okinaka, R.T.; Chantratita, N.; Beg, S.; Stratilo, C.W.; Olive, A.J.; Soltes, G.; Russell, M.L.; Limmathurotsakul, D.; Norton, R.E.; Ni, S.X.; Picking, W.D.; Jackson, P.J.; Stewart, D.I.; Tsvetnitsky, V.; Picking, W.L.; Cherwonogrodzky, J.W.; Ketheesan, N.; Peacock, S.J.; Wiersma, E.J. Evaluating burkholderia pseudomallei bip proteins as vaccines and bip antibodies as detection agents. FEMS Immunol. Med. Microbiol., 2008, 52, 78-87.
26. McClean, S.; Callaghan, M. Burkholderia cepacia complex: Epithelial cell-pathogen confrontations and potential for therapeutic intervention. J. Med. Microbiol., 2009, 58, 1-12.
27. Mariappan, V.; Vellasamy, K.M.; Thimma, J.S.; Hashim, O.H.; Vadivelu, J. Identification of immunogenic proteins from burkholderia cepacia secretome using proteomic analysis. Vaccine, 2010, 28, 1318-1324.
28. Stephens, D.S. Conquering the meningococcus. FEMS Microbiol. Rev., 2007, 31, 3-14.
29. Mendum, T.A.; Newcombe, J.; McNeilly, C.L.; McFadden, J. Towards the immunoproteome of neisseria meningitidis. PLoS One, 2009, 4, e5940.
30. Rohani, P.; Drake, J.M. The decline and resurgence of pertussis in the us. Epidemics, 2011, 3, 183-188.
31. Marzouqi, I.; Richmond, P.; Fry, S.; Wetherall, J.; Mukkur, T. Development of improved vaccines against whooping cough: Current status. Hum. Vaccin., 2010, 6, 543-553.
32. Trollfors, B. Factors influencing antibody responses to acellular pertussis vaccines. Dev. Biol. Stand., 1997, 89, 279-282.
33. Tefon, B.E.; Maass, S.; Ozcengiz, E.; Becher, D.; Hecker, M.; Ozcengiz, G. A comprehensive analysis of bordetella pertussis surface proteome and identification of new immunogenic proteins. Vaccine, 2011, 29, 3583-3595.
34. Altindis, E.; Tefon, B.E.; Yildirim, V.; Ozcengiz, E.; Becher, D.; Hecker, M.; Ozcengiz, G. Immunoproteomic analysis of bordetella pertussis and identification of new immunogenic proteins. Vaccine, 2009, 27, 542-548.
35. Zhu, Y.Z.; Cai, C.S.; Zhang, W.; Guo, H.X.; Zhang, J.P.; Ji, Y.Y.; Ma, G.Y.; Wu, J.L.; Li, Q.T.; Lu, C.P.; Guo, X.K. Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (wcv). PLoS One, 2010, 5, e13915.
36. Gilleland, H.E., Jr.; Parker, M.G.; Matthews, J.M.; Berg, R.D. Use of a purified outer membrane protein f (porin) preparation of pseudomonas aeruginosa as a protective vaccine in mice. Infect. Immun., 1984, 44, 49-54.
37. Martin, N.L.; Rawling, E.G.; Wong, R.S.; Rosok, M.; Hancock, R.E. Conservation of surface epitopes in pseudomonas aeruginosa outer membrane porin protein oprf. FEMS Microbiol. Lett., 1993, 113, 261-266.
38. Saint-Onge, A.; Romeyer, F.; Lebel, P.; Masson, L.; Brousseau, R. Specificity of the pseudomonas aeruginosa pao1 lipoprotein i gene as a DNA probe and pcr target region within the pseudomonadaceae. J. Gen. Microbiol., 1992, 138, 733-741.
39. von Specht, B.; Knapp, B.; Hungerer, K.; Lucking, C.; Schmitt, A.; Domdey, H. Outer membrane proteins of pseudomonas aeruginosa as vaccine candidates. J. Biotechnol., 1996, 44, 145-153.
40. Matthews-Greer, J.M.; Gilleland, H.E., Jr. Outer membrane protein f (porin) preparation of pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model. J. Infect. Dis., 1987, 155, 1282-1291.
41. Moon, M.M.; Hazlett, L.D.; Hancock, R.E.; Berk, R.S.; Barrett, R. Monoclonal antibodies provide protection against ocular pseudomonas aeruginosa infection. Invest. Ophthalmol. Vis. Sci., 1988, 29, 1277-1284.
42. Hartl, D.; Griese, M.; Kappler, M.; Zissel, G.; Reinhardt, D.; Rebhan, C.; Schendel, D.J.; Krauss-Etschmann, S. Pulmonary t(h)2 response in pseudomonas aeruginosa-infected patients with cystic fibrosis. J. Allergy Clin. Immunol., 2006, 117, 204-211.
43. Moser, C.; Jensen, P.O.; Kobayashi, O.; Hougen, H.P.; Song, Z.; Rygaard, J.; Kharazmi, A.; N, H.b. Improved outcome of chronic pseudomonas aeruginosa lung infection is associated with induction of a th1-dominated cytokine response. Clin. Exp. Immunol., 2002, 127, 206-213.
44. Bumann, D.; Behre, C.; Behre, K.; Herz, S.; Gewecke, B.; Gessner, J.E.; von Specht, B.U.; Baumann, U. Systemic, nasal and oral live vaccines against pseudomonas aeruginosa: A clinical trial of immunogenicity in lower airways of human volunteers. Vaccine, 2010, 28, 707-713.
45. Peluso, L.; de Luca, C.; Bozza, S.; Leonardi, A.; Giovannini, G.; Lavorgna, A.; De Rosa, G.; Mascolo, M.; Ortega De Luna, L.; Catania, M.R.; Romani, L.; Rossano, F. Protection against pseudomonas aeruginosa lung infection in mice by recombinant oprf-pulsed dendritic cell immunization. BMC Microbiol., 2010, 10, 9.
46. Fito-Boncompte, L.; Chapalain, A.; Bouffartigues, E.; Chaker, H.; Lesouhaitier, O.; Gicquel, G.; Bazire, A.; Madi, A.; Connil, N.; Veron, W.; Taupin, L.; Toussaint, B.; Cornelis, P.; Wei, Q.; Shioya, K.; Deziel, E.; Feuilloley, M.G.; Orange, N.; Dufour, A.; Chevalier, S. Full virulence of pseudomonas aeruginosa requires oprf. Infect. Immun., 2011, 79, 1176-1186.
47. Hoboth, C.; Hoffmann, R.; Eichner, A.; Henke, C.; Schmoldt, S.; Imhof, A.; Heesemann, J.; Hogardt, M. Dynamics of adaptive microevolution of hypermutable pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis. J. Infect. Dis., 2009, 200, 118-130.
48. Doring, G.; Meisner, C.; Stern, M. A double-blind randomized placebo-controlled phase iii study of a pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. USA., 2007, 104, 11020-11025.
49. Campodonico, V.L.; Llosa, N.J.; Grout, M.; Doring, G.; Maira-Litran, T.; Pier, G.B. Evaluation of flagella and flagellin of pseudomonas aeruginosa as vaccines. Infect. Immun., 2010, 78, 746-755.
50. Weimer, E.T.; Lu, H.; Kock, N.D.; Wozniak, D.J.; Mizel, S.B. A fusion protein vaccine containing oprf epitope 8, opri, and type a and b flagellins promotes enhanced clearance of nonmucoid pseudomonas aeruginosa. Infect. Immun., 2009, 77, 2356-2366.
51. Upritchard, H.G.; Cordwell, S.J.; Lamont, I.L. Immunoproteomics to examine cystic fibrosis host interactions with extracellular pseudomonas aeruginosa proteins. Infect. Immun., 2008, 76, 4624-4632.
52. Ying, T.; Wang, H.; Li, M.; Wang, J.; Wang, J.; Shi, Z.; Feng, E.; Liu, X.; Su, G.; Wei, K.; Zhang, X.; Huang, P.; Huang, L. Immunoproteomics of outer membrane proteins and extracellular proteins of shigella flexneri 2a 2457t. Proteomics, 2005, 5, 4777-4793.
53. Yamaguchi, H.; Osaki, T.; Kai, M.; Taguchi, H.; Kamiya, S. Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of helicobacter pylori. Infect. Immun., 2000, 68, 3448-3454.
54. Yamaguchi, H.; Yamamoto, T.; Taguchi, H.; Ogata, S. Yersinia enterocolitica immunodominant 60 kda antigen, common to a broad range of bacteria, is a heat-shock protein. J. Gen. Microbiol., 1990, 136, 1091-1097.
55. Sinha, K.; Bhatnagar, R. Groel provides protection against bacillus anthracis infection in balb/c mice. Mol. Immunol., 2010, 48, 264-271.
56. Khan, M.N.; Shukla, D.; Bansal, A.; Mustoori, S.; Ilavazhagan, G. Immunogenicity and protective efficacy of groel (hsp60) of streptococcus pneumoniae against lethal infection in mice. FEMS Immunol. Med. Microbiol., 2009, 56, 56-62.
57. Balasubramanian, S.; Kannan, T.R.; Hart, P.J.; Baseman, J.B. Amino acid changes in elongation factor tu of mycoplasma pneumoniae and mycoplasma genitalium influence fibronectin binding. Infect. Immun., 2009, 77, 3533-3541.
58. Granato, D.; Bergonzelli, G.E.; Pridmore, R.D.; Marvin, L.; Rouvet, M.; Corthesy-Theulaz, I.E. Cell surface-associated elongation factor tu mediates the attachment of lactobacillus johnsonii ncc533 (la1) to human intestinal cells and mucins. Infect. Immun., 2004, 72, 2160-2169.
59. Kunert, A.; Losse, J.; Gruszin, C.; Huhn, M.; Kaendler, K.; Mikkat, S.; Volke, D.; Hoffmann, R.; Jokiranta, T.S.; Seeberger, H.; Moellmann, U.; Hellwage, J.; Zipfel, P.F. Immune evasion of the human pathogen pseudomonas aeruginosa: Elongation factor tuf is a factor h and plasminogen binding protein. J. Immunol., 2007, 179, 2979-2988.
60. Sellman, B.R.; Howell, A.P.; Kelly-Boyd, C.; Baker, S.M. Identification of immunogenic and serum binding proteins of staphylococcus epidermidis. Infect. Immun., 2005, 73, 6591-6600.
61. Kovach, Z.; Kaakoush, N.O.; Lamb, S.; Zhang, L.; Raftery, M.J.; Mitchell, H. Immunoreactive proteins of campylobacter concisus, an emergent intestinal pathogen. FEMS Immunol. Med. Microbiol., 2011, 63, 387-396.
62. Carbonetti, N.H.; Artamonova, G.V.; Andreasen, C.; Dudley, E.; Mays, R.M.; Worthington, Z.E. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by bordetella pertussis and identification of an immunodominant lipoprotein. Infect. Immun., 2004, 72, 3350-3358.
63. Nieves, W.; Heang, J.; Asakrah, S.; Honer zu Bentrup, K.; Roy, C.J.; Morici, L.A. Immunospecific responses to bacterial elongation factor tu during burkholderia infection and immunization. PLoS One, 2010, 5, e14361.
64. Fulton, K.M.; Zhao, X.; Petit, M.D.; Kilmury, S.L.; Wolfraim, L.A.; House, R.V.; Sjostedt, A.; Twine, S.M. Immunoproteomic analysis of the human antibody response to natural tularemia infection with type a or type b strains or lvs vaccination. Int. J. Med. Microbiol., 2011, 301, 591-601.
65. Twine, S.M.; Petit, M.D.; Fulton, K.M.; House, R.V.; Conlan, J.W. Immunoproteomics analysis of the murine antibody response to vaccination with an improved francisella tularensis live vaccine strain (lvs). PLoS One, 2010, 5, e10000.
66. Nally, J.E.; Whitelegge, J.P.; Bassilian, S.; Blanco, D.R.; Lovett, M.A. Characterization of the outer membrane proteome of leptospira interrogans expressed during acute lethal infection. Infect. Immun., 2007, 75, 766-773.